Genetic Susceptibility Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA])

PRIMARY OBJECTIVES:

I. Evaluate the independent association of common genetic polymorphisms involved in folate,
vitamin A, and related metabolic and transport pathways and the risk of neuroblastoma (NB).

II. Evaluate the joint effects of multiple genes on the risk of NB. III. Evaluate the effects
of gene-exposure interactions on the risk of NB. IV. Evaluate genetic effects within NB
subgroups defined by age at diagnosis and a Children?s Oncology group classification schema
based on age, v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
(MYCN) oncogene status, histology, and deoxyribonucleic acid (DNA) ploidy.

V. Recontact mothers of participating NENA case children, conduct brief web-based screen to
ascertain whether the pregnancy including the index NENA child was a multiple (twin, triplet,
etc), whether the mother knew if the children were monozygotic (MZ) or dizygotic (DZ), and
obtain a complete pregnancy history.

VI. Request a saliva sample from the other twin/multiple sibling of the NENA child.

VII. Extract DNA from saliva samples and securely store. VIII. Clean new survey data and
merge with main NENA study database.

OUTLINE:

The biologic mother of the patient is asked to complete a Diet History Questionnaire about
diet during pregnancy, and information on demographics, lifestyle factors, medication used
during pregnancy, history of breast feeding, and family history of cancer or birth defects.
Parents are given ORAgene saliva collection kits for self-collection. Saliva bio-specimen
samples are collected from both biologic parents and the patient. Tissue samples previously
stored in a tissue bank are obtained for deceased patients, if available. DNA is extracted
from samples, amplified and analyzed using real-time polymerase chain reaction (PCR)
quantitation assay, and genotyped using single nucleotide polymorphisms.

Inclusion Criteria:

- Primary diagnosis of neuroblastoma made at a North American COG institution

- Diagnosed between 12/24/2007- 7/31/2013

- Diagnosed at < 6 years of age

- Biological mother is alive and willing to participate

- Questionnaire respondents must understand English or Spanish

- Are only those participating in CCRN who have agreed to be contacted for future
studies